AU2002310461B2 - Olopatadine formulations for topical administation - Google Patents

Olopatadine formulations for topical administation Download PDF

Info

Publication number
AU2002310461B2
AU2002310461B2 AU2002310461A AU2002310461A AU2002310461B2 AU 2002310461 B2 AU2002310461 B2 AU 2002310461B2 AU 2002310461 A AU2002310461 A AU 2002310461A AU 2002310461 A AU2002310461 A AU 2002310461A AU 2002310461 B2 AU2002310461 B2 AU 2002310461B2
Authority
AU
Australia
Prior art keywords
solution
polyvinylpyrrolidone
olopatadine
composition
ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002310461A
Other languages
English (en)
Other versions
AU2002310461A1 (en
Inventor
Haresh G. Bhagat
Joseph Paul Bullock
Ernesto J. Castillo
Suresh C. Dixit
Wesley Wehsin Han
Onkar N. Singh
Huixiang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23162841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002310461(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002310461A1 publication Critical patent/AU2002310461A1/en
Application granted granted Critical
Publication of AU2002310461B2 publication Critical patent/AU2002310461B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: ALCON, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002310461A 2001-06-27 2002-06-19 Olopatadine formulations for topical administation Expired AU2002310461B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30131501P 2001-06-27 2001-06-27
US60/301,315 2001-06-27
PCT/US2002/019417 WO2003002093A1 (en) 2001-06-27 2002-06-19 Olopatadine formulations for topical administration

Publications (2)

Publication Number Publication Date
AU2002310461A1 AU2002310461A1 (en) 2003-05-15
AU2002310461B2 true AU2002310461B2 (en) 2006-05-18

Family

ID=23162841

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002310461A Expired AU2002310461B2 (en) 2001-06-27 2002-06-19 Olopatadine formulations for topical administation

Country Status (20)

Country Link
US (2) US6995186B2 (cg-RX-API-DMAC7.html)
EP (1) EP1399127B1 (cg-RX-API-DMAC7.html)
JP (5) JP4827374B2 (cg-RX-API-DMAC7.html)
KR (1) KR100884711B1 (cg-RX-API-DMAC7.html)
CN (1) CN1211125C (cg-RX-API-DMAC7.html)
AR (1) AR034619A1 (cg-RX-API-DMAC7.html)
AT (1) ATE295149T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002310461B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0210707B8 (cg-RX-API-DMAC7.html)
CA (1) CA2447924C (cg-RX-API-DMAC7.html)
DE (1) DE60204142T2 (cg-RX-API-DMAC7.html)
DK (1) DK1399127T3 (cg-RX-API-DMAC7.html)
ES (1) ES2238574T3 (cg-RX-API-DMAC7.html)
GC (1) GC0000397A (cg-RX-API-DMAC7.html)
MX (1) MXPA03011947A (cg-RX-API-DMAC7.html)
PL (1) PL205565B1 (cg-RX-API-DMAC7.html)
PT (1) PT1399127E (cg-RX-API-DMAC7.html)
TW (1) TWI231759B (cg-RX-API-DMAC7.html)
WO (1) WO2003002093A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200308771B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055152A1 (en) * 2008-08-26 2010-03-04 Trutek Corporation Antihistamine and antihistamine-like nasal application, products, and method
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
US20070275853A1 (en) * 2004-04-08 2007-11-29 Kyowa Hakko Kogyo Co., Ltd. Solid Products with Improved Stability and Method for Producing the Same
JPWO2005102313A1 (ja) * 2004-04-21 2007-08-16 協和醗酵工業株式会社 慢性副鼻腔炎の予防および／または治療剤
ZA200610350B (en) * 2004-06-28 2008-12-31 Alcon Inc Topical formulations for treating allergic diseases
PL1814538T3 (pl) * 2004-11-24 2010-02-26 Alcon Inc Sposób dostarczania donosowego sprayu
WO2006097458A1 (en) * 2005-03-15 2006-09-21 Nycomed Gmbh Novel combination
ES2437077T3 (es) 2005-07-08 2014-01-08 Senju Pharmaceutical Co., Ltd. Preparado oftálmico de absorción percutánea que comprende olopatadina
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
KR20140032505A (ko) * 2006-11-09 2014-03-14 알콘 리서치, 리미티드 약물 전달용 수불용성 폴리머 매트릭스
ZA200903649B (en) * 2006-12-18 2010-08-25 Alcon Res Ltd Devices and methods for ophthalmic drug delivery
WO2008093358A2 (en) * 2007-01-29 2008-08-07 Sun Pharmaceutical Industries Limited Aqueous topical solution containing olopatadine
SI2114367T1 (sl) * 2007-02-07 2016-01-29 Novartis Ag Formulacije olopatadina za topično nazalno dajanje
WO2008120249A1 (en) * 2007-03-30 2008-10-09 Sifi S.P.A. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
EP2189157A4 (en) * 2007-09-06 2012-10-31 Kyowa Hakko Kirin Co Ltd EYE DROPPING WITH DIBENZO [b, e] OXEPINE DERIVATIVE
MX2010011755A (es) * 2008-05-19 2010-11-25 Alcon Res Ltd Composiciones farmaceuticas que tienen polimero de carboxivinilo y polimero de povidona.
EP2318101A1 (en) * 2008-08-26 2011-05-11 Trutek Corp. Electrostatically charged mask filter products and method for increased filtration efficiency
JP2012509250A (ja) * 2008-08-28 2012-04-19 トルテック コーポレーション 抗ヒスタミン及び抗ヒスタミン様経鼻適用製品及び方法
US9458198B1 (en) 2009-06-26 2016-10-04 Shire Orphan Therapies Gmbh Cyclic peptide-based NPR-B agonists
PT2453872E (pt) * 2009-07-17 2013-10-30 Alcon Res Ltd Regime de pulverização nasal de olopatadina para crianças
WO2011027322A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
US8546523B2 (en) 2009-09-25 2013-10-01 Alcon Research, Ltd. NPR-B agonists
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
KR20120091037A (ko) * 2009-10-01 2012-08-17 알콘 리서치, 리미티드 올로파타딘 조성물 및 그의 용도
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
WO2011075471A2 (en) 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
JP2013535451A (ja) * 2010-07-21 2013-09-12 アルコン リサーチ， リミテッド 増強された溶解度特徴を有する薬学的組成物
CA2812164A1 (en) * 2010-11-08 2012-05-18 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
TWI544922B (zh) * 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
CN102885767A (zh) * 2012-11-02 2013-01-23 江苏吉贝尔药业有限公司 一种新的盐酸奥洛他定滴眼液及其制备方法
MA47418A (fr) 2017-02-01 2021-06-02 Takeda Pharmaceuticals Co Composés et compositions pour le traitement de troubles ophtalmiques
WO2018235935A1 (ja) * 2017-06-23 2018-12-27 参天製薬株式会社 水溶性粘稠化剤を含有する医薬組成物
JP7037349B2 (ja) * 2017-06-23 2022-03-16 参天製薬株式会社 水溶性粘稠化剤を含有する医薬組成物
AU2020398812A1 (en) * 2019-12-06 2022-06-30 Toko Yakuhin Kogyo Co., Ltd. Rhinenchysis composition containing olopatadine
EP4129341A4 (en) * 2020-03-31 2024-04-24 Santen Pharmaceutical Co., Ltd. AQUEOUS OPHTHALMIC COMPOSITION CONTAINING A SILVER SALT BY MEANS OF WHICH A RESIN CONTAINER IS FILLED
CN111700860A (zh) * 2020-07-09 2020-09-25 浙江尖峰药业有限公司 盐酸奥洛他定滴眼液及其制备方法
CN119318630B (zh) * 2024-10-16 2025-08-22 苏州欧康维视生物科技有限公司 一种阿托品药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001054687A1 (en) * 2000-01-25 2001-08-02 Alcon Universal Ltd. Ophthalmic anti-allergy compositions suitable for use with contact lenses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370324A (en) 1980-09-17 1983-01-25 Bernstein Joel E Method and composition for treating and preventing irritation of the eyes
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) * 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
ATE84968T1 (de) * 1987-11-13 1993-02-15 Asta Medica Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
JP3662944B2 (ja) 1993-08-24 2005-06-22 協和醗酵工業株式会社 点鼻剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US5641805A (en) * 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
WO1998056381A1 (en) * 1997-06-09 1998-12-17 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
DK1037627T3 (da) 1998-07-14 2001-10-01 Alcon Lab Inc Anvendelse af 11-(3-dimethylamino-propyliden)-6, 11-dihydrodibenz[b,e]oxepin-2-eddikesyre og af farmaceutisk acceptable salte deraf til fremstillingen af et lægemiddel til behandlingen af non-allergiske...
BR9914799A (pt) * 1998-10-27 2001-07-10 Alcon Lab Inc Sistema conservante para composições farmacêuticas administráveis topicamente contendo um sabão de ácido graxo/aminoácido
US6146622A (en) * 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
US6174914B1 (en) * 1999-06-15 2001-01-16 Alcon Laboratories, Inc. Method of inhibiting cytokine release from human ocular cells
TR200200724T2 (tr) 1999-09-21 2002-06-21 Alcon Laboratories, Inc. Cilde sürülebilen farmasötik bileşimlerin antimikrobik etkisinin arttırılması için yağlı asit/amino asit sabunlarının kullanımı
EP1242090A4 (en) 1999-11-18 2004-02-11 Alcon Inc USE OF AN H1 ANTAGONIST AND A SAFE STEROID IN THE TREATMENT OF EYE CONDITIONS
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
JP2006508138A (ja) 2002-11-12 2006-03-09 アルコン，インコーポレイテッド アレルギー性鼻炎を処置するための抗アレルギー剤およびステロイドの使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001054687A1 (en) * 2000-01-25 2001-08-02 Alcon Universal Ltd. Ophthalmic anti-allergy compositions suitable for use with contact lenses

Also Published As

Publication number Publication date
ATE295149T1 (de) 2005-05-15
US6995186B2 (en) 2006-02-07
CN1211125C (zh) 2005-07-20
PL367780A1 (en) 2005-03-07
DK1399127T3 (da) 2005-06-13
BR0210707A (pt) 2004-07-20
US7402609B2 (en) 2008-07-22
CA2447924A1 (en) 2003-01-09
BRPI0210707B8 (pt) 2021-05-25
ES2238574T3 (es) 2005-09-01
WO2003002093A1 (en) 2003-01-09
DE60204142T2 (de) 2005-10-06
JP2013127005A (ja) 2013-06-27
JP4827374B2 (ja) 2011-11-30
HK1059573A1 (en) 2004-07-09
AR034619A1 (es) 2004-03-03
DE60204142D1 (de) 2005-06-16
MXPA03011947A (es) 2004-03-26
KR20040025919A (ko) 2004-03-26
CA2447924C (en) 2009-11-03
JP2009114213A (ja) 2009-05-28
PT1399127E (pt) 2005-07-29
JP2004536096A (ja) 2004-12-02
KR100884711B1 (ko) 2009-02-19
TWI231759B (en) 2005-05-01
JP2010150292A (ja) 2010-07-08
EP1399127B1 (en) 2005-05-11
JP5328947B2 (ja) 2013-10-30
US20030055102A1 (en) 2003-03-20
CN1525849A (zh) 2004-09-01
US20050158387A1 (en) 2005-07-21
EP1399127A1 (en) 2004-03-24
JP2012107046A (ja) 2012-06-07
GC0000397A (en) 2007-03-31
BRPI0210707B1 (pt) 2015-08-04
PL205565B1 (pl) 2010-05-31
ZA200308771B (en) 2005-01-26

Similar Documents

Publication Publication Date Title
AU2002310461B2 (en) Olopatadine formulations for topical administation
AU2002310461A1 (en) Olopatadine formulations for topical administation
CA2839847C (en) Ophthalmic compositions containing a synergistic combination of two polymers
US4425344A (en) Compositions for the treatment of glaucoma containing triamterene
EP2586426B1 (en) Carboxyvinyl polymer-containing nanoparticle suspensions
RO115409B1 (ro) Compozitie oftalmica cu viscozitate scazuta
US9801813B2 (en) Preservative-free ophthalmic pharmaceutical formulation
AU3455601A (en) Ophthalmic anti-allergy compositions suitable for use with contact lenses
RO111988B1 (ro) Preparat oftalmologic
JP5149308B2 (ja) 局所的鼻腔投与のためのオロパタジンの製剤
CA2758858C (en) Aqueous ophthalmic compositions containing anionic therapeutic agents
HK1059573B (en) Olopatadine formulations for topical administration
CA2002552C (en) Pharmaceutical aqueous solution for ophthalmic use comprising a water solube pharmaceutically acceptable acid addition salt of ibopamine
KR20100032018A (ko) 항히스타민제를 포함하는 점안용 조성물
HK1178802B (en) Carboxyvinyl polymer-containing nanoparticle suspensions
HK1012556A1 (en) Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
HK1012556B (en) Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NOVARTIS AG

Free format text: FORMER OWNER(S): ALCON, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired